Background
Urothelial carcinoma (UC) exhibits extensive infiltration of tumor-associated macrophages (TAMs). As the most frequently altered gene in UC, TP53 is recognized not only as a guardian of genomic integrity, but also as a potential architect o…
Maintenance of anticancer immunity without compromising immune tolerance remains a challenge. Immunosuppressive regulatory T cells (Tregs) are the guardians of immune tolerance that underpin prevention of autoimmune responses. Tregs express checkpoint…
Despite the success of immunotherapy, chemotherapy remains the backbone of front-line therapy for most patients with cancer. Immune checkpoint inhibitors, T cell engagers, and adoptive cell therapies have traditionally been relegated to second-line or…
Background
Despite its viral etiology and immunogenic features, cervical cancer shows limited and often short-lived benefit from programmed cell death protein 1 blockade, currently the only approved immunotherapy for this disease. This limitation high…
Background
Chimeric antigen receptor (CAR) T-cell therapy is a promising immunotherapy for patients with refractory or relapsed lymphoma or leukemia. However, inefficient activity and insufficient persistence of CAR T cells impede the durability of it…
Background
Immune checkpoint blockade (ICB) has revolutionized cancer therapy, yet resistance—both primary and acquired—remains a significant obstacle, affecting the majority of patients.
Methods
Here, we leverage a large-scale, real-worl…
Background
Relapsed or refractory (R/R) B-cell non-Hodgkin’s lymphoma (B-NHL) remains a major therapeutic challenge despite CD19-directed chimeric antigen receptor (CAR) T-cell therapies, with treatment failure often driven by antigen escape and…
Background
Dysbiosis of gut microbiome leads to resistance to immunotherapy in various advanced solid tumors. CJRB-101 is a live biotherapeutic product consisting of a novel strain belonging to the species Leuconostoc mesenteroides. To modulate the tu…
Background
B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy has demonstrated substantial clinical benefit in relapsed/refractory multiple myeloma (R/R MM). Nonetheless, immune escape and therapeutic resistance r…
Background
Circadian biology suggests that synchronizing immune checkpoint inhibitor (ICI) dosing with morning peaks in immune activation could improve clinical outcomes, but well-powered studies using appropriate causal inference methodology are spar…
